Mark Pegram, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Novartis
    Topic: 
    Consultant
    Date added: 
    04/07/2022
    Relationship end date: 
    12/31/2024
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Gilead
    Topic: 
    Consultant
    Date added: 
    04/10/2023
    Relationship end date: 
    12/31/2024
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Roche/Genentech
    Topic: 
    Consultant
    Date added: 
    01/08/2024
    Relationship end date: 
    12/31/2024
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Astra-Zeneca/Daiichi Sankyo
    Topic: 
    Consultant
    Date added: 
    01/08/2024
    Relationship end date: 
    12/31/2024
Return to Binaytara Hematology and Breast Cancer Conference, Fresno